Key facts
- This page summarizes David M. Reese's Form 4 filing for AMGEN INC (AMGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2022, 21:38.
David M. Reese - 02 Nov 2022 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- EVP, Research and Development
- Issuer ticker
- AMGN
- Reported as of
- 02 Nov 2022
- Net transaction value
- -$663,826
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2022, 21:38:31 UTC
- Prior SEC filing
- 09 May 2022
- Next SEC filing
- 08 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David M. Reese
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David M. Reese filed Form 4 for AMGEN INC (AMGN) on 03 Nov 2022.
Change
- Previous filing in this sequence was filed on 09 May 2022.
- Current net transaction value: -$663,826.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Tax liability
- Transaction value
- $663,826
- Shares
- -2,440
- Change %
- -4.8%
- Price
- $272.06
- Shares after
- 48,136
- Date
- 02 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
2,440 shares issuable upon the vesting of Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) on 11/2/2022 were withheld by the Company to cover related tax withholding obligations.
Footnote F2
These shares include the following RSUs granted under the Company's equity plans: 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Footnote F3
These shares include 611 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.